DiaMedica Therapeutics (DMAC) Receivables - Net (2017 - 2026)
DiaMedica Therapeutics (DMAC) reported Receivables - Net of $301000.0 for Q1 2026, up 18.97% on a YoY basis from $253000.0 in Q1 2025, and up 16.67% quarter-over-quarter from $258000.0 in Q4 2025.
DiaMedica Therapeutics (DMAC) Receivables - Net (2017 - 2026) Analysis & Trends
DiaMedica Therapeutics has reported Receivables - Net for 10 years, with the latest figure at $301000.0 in Q1 2026.
- For the quarter ending Q1 2026, Receivables - Net rose 18.97% year-over-year to $301000.0; the trailing twelve-month figure through Mar 2026 stood at $301000.0 (up 18.97% YoY), and the FY2025 full-year result was $258000.0, up 9.32% from the prior year.
- Receivables - Net for Q1 2026 stood at $301000.0, up from $258000.0 in the prior quarter.
- The five-year high for Receivables - Net was $399000.0 in Q1 2024, with the low at $57000.0 in Q1 2023.
- Historically, Receivables - Net has averaged $228588.2 across 5 years, with a median of $253000.0 in 2025.
- Annual changes were most pronounced in 2023 — Receivables - Net slumped 66.07% — and 2024, when it surged 600.0%.
- DiaMedica Therapeutics' Receivables - Net stood at $82000.0 in 2022, then surged by 350.0% to $369000.0 in 2023, then tumbled by 36.04% to $236000.0 in 2024, then climbed by 9.32% to $258000.0 in 2025, then rose by 16.67% to $301000.0 in 2026.
- The last three Receivables - Net figures came in at $301000.0 (Q1 2026), $258000.0 (Q4 2025), and $260000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | DiaMedica Therapeutics | 285.11 Mn | 233.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 301,000.00 |
| Mar 31, 2026 | 301,000.00 |
| Dec 31, 2025 | 258,000.00 |
| Dec 31, 2025 | 258,000.00 |
| Sep 30, 2025 | 260,000.00 |
| Sep 30, 2025 | 260,000.00 |
| Jun 30, 2025 | 161,000.00 |
| Jun 30, 2025 | 161,000.00 |
| Mar 31, 2025 | 253,000.00 |
| Mar 31, 2025 | 253,000.00 |
| Dec 31, 2024 | 236,000.00 |
| Dec 31, 2024 | 236,000.00 |
| Sep 30, 2024 | 290,000.00 |
| Sep 30, 2024 | 290,000.00 |
| Jun 30, 2024 | 391,000.00 |
| Jun 30, 2024 | 391,000.00 |
| Mar 31, 2024 | 399,000.00 |
| Mar 31, 2024 | 399,000.00 |
| Dec 31, 2023 | 369,000.00 |
| Dec 31, 2023 | 369,000.00 |